spec sheet9 rows
Alvameline was Lundbeck's attempt at a smarter cholinergic drug for Alzheimer's disease. Rather than pushing every muscarinic receptor at once, the way older agonists did, it was built to be a partial agonist at M1, the postsynaptic receptor thought to carry the cholinergic signal for memory, while blocking M2 and M3, the receptors behind the presynaptic brake and behind most of the salivation, sweating and gut cramping that had sunk earlier compounds. In animals the design held up: it produced none of the tremor, hypothermia or drooling that non-selective agonists cause in mice, and it read as its own thing in drug discrimination rather than as a copy of either a full agonist or a cholinesterase inhibitor. The clinic went the other way. A six-month trial across 29 centres randomised 496 people with probable Alzheimer's disease to placebo or 25, 50 or 100 mg three times daily and found nothing on either primary endpoint; among completers the highest dose actually trended worse, and side effects still climbed with dose. Development stopped. The molecule had a brief second life as a candidate bladder antimuscarinic, where the M3 blockade was the point rather than a design compromise, and nothing came of that either.
- Avoided the tremor, hypothermia and salivation that non-selective muscarinic agonists cause in mice
- Shifted amyloid precursor protein processing in cell studies, the mechanism that made it look disease-modifying on paper
- Reached a tolerated oral dose of 150 mg three times daily in Alzheimer's patients
- Remains a clean reference compound for M1-agonist and M2/M3-antagonist pharmacology
- Improved Morris water maze performance in rats after traumatic brain injury
- Attenuated the post-traumatic loss of forebrain choline acetyltransferase immunoreactivity in rats
- Increased secreted amyloid precursor protein through m1 in transfected cells and in rat hippocampal slices
- Produced none of the tremor, hypothermia or salivation that non-selective muscarinic agonists cause in mice
- No cognitive benefit at any dose in a 496-patient, six-month, placebo-controlled Alzheimer's trial
- A trend toward worse cognition at the highest dose among trial completers
- Dizziness, nausea, diarrhoea, fatigue, increased sweating and anorexia, all rising with dose
- Gastrointestinal effects capped dosing; 200 mg three times daily was stopped after three days
- Discontinued, never approved, and with no long-term human safety data of any kind
- Cholinergic adverse events at every dose tested in Alzheimer's patients, including increased salivation, dizziness and gastrointestinal symptoms
- Gastrointestinal effects stopped the 200 mg three times daily panel after three days
- Dizziness, nausea, diarrhoea, fatigue, sweating and anorexia all rose with dose in the phase 3 trial
Overview
The most rational design of the failed muscarinic agonists, and for that reason the most damaging to the hypothesis. The idea was right, the rodent data supported it, and it still produced cholinergic adverse events at every dose tested in patients and a trend toward worsening at the top dose.
- The dose-finding study in Alzheimer's patients tried a slow titration to see whether people could be walked up to higher doses; it made no difference, and 200 mg three times daily was still intolerable.
- Its M2 and M3 blockade later got it tested on isolated human bladder tissue as an overactive-bladder candidate, an unusual second career for a failed dementia drug.
- Alvameline's phase 3 trial did not merely fail to help; among the patients who completed it, the highest dose trended toward worse cognition than placebo.
- Its second career was as a bladder drug, where the M3 blockade that had been a design compromise in dementia became the intended effect; it antagonised carbachol-induced contraction of human detrusor with a pKb of 6.2, against 7.9 for oxybutynin.
Mechanism
Alvameline is a partial at M1 with activity at M2 and M3, a combination chosen so that the drug would push the postsynaptic receptor thought to carry the memory signal while blocking both the presynaptic autoreceptor that shuts release down and the peripheral receptor behind salivation, sweating and gut cramp [6]. The binding affinity was excellent and the M1 function was not; the concentration needed to depolarise the rat superior cervical ganglion through M1 is roughly two hundred times higher than its binding affinity against an radioligand, so most of that affinity is for a receptor state it cannot fully drive.
In mice it did not stimulate phosphoinositide hydrolysis in vivo, which is the M1-coupled second messenger the entire design existed to activate [8]. The half of the design did hold up in animals: unlike non-selective agonists and cholinesterase inhibitors, alvameline produced no hypothermia, tremor or salivation in mice, no change in mean blood pressure in anaesthetised rats or cats, and it substituted completely for a partial M1/M2 in drug discrimination while substituting only weakly for a non-selective agonist [6].
In cells expressing m1 but not m2, and in fresh rat hippocampal slices, it did increase secreted amyloid precursor protein, with lower intrinsic activity than carbachol, which is the non-amyloidogenic processing shift activation is supposed to produce [4].
receptor fingerprint
receptors, rat brain (-preferring state)Partial agonist binding signature
M1 (CHRM1)Partial agonist
M2 (CHRM2)Antagonist at cardiac M2; agonist EC50 above 51 micromolar in guinea pig atrium
M2 and M3 in smooth muscleWeak agonist in guinea pig ileum
receptors, human detrusorAntagonist
Safetyrisks and cautions, not medical advice
The clinical tolerability data are unusually blunt. In a bridging study in patients with Alzheimer's disease, cholinergic adverse events including increased salivation, dizziness and gastrointestinal symptoms were observed at every dose studied; dosing of the 200 mg three times daily panel was stopped after three days for unacceptable gastrointestinal effects, the fixed-dose maximum tolerated dose was set at 150 mg three times daily, and a titration schedule did not improve overall tolerability [2].
In the phase 3 trial, dizziness, nausea, diarrhoea, fatigue, increased sweating and anorexia all increased with dose [1]. The M2 and M3 blockade therefore did not deliver a clean cholinergic profile in humans even though it had in mice, where the compound produced none of the tremor, hypothermia or salivation that non-selective agonists cause [6]. Heart rate rose by up to 37% in anaesthetised rats, which is consistent with blockade of cardiac M2 rather than agonism at it, and is the mirror image of the bradycardia sabcomeline produced [6].
History
Alvameline came from H. Lundbeck in Copenhagen and carried the code Lu 25-109; Lundbeck's own drug metabolism department mapped its metabolite tree across mice, rats, dogs and humans and showed that only the analogues with a log D above about -0.83 crossed the blood-brain barrier [7] [8]. The clinical programme ran a bridging study to set the maximum tolerated dose [2] and then a six-month randomised, double-blind, placebo-controlled trial in which 496 patients with probable Alzheimer's disease at 29 centres received placebo or 25, 50 or 100 mg three times daily.
It produced no significant difference on either primary endpoint, the cognitive subscale of the Alzheimer's Disease Assessment Scale and the clinical global impression of change, or on the secondary endpoints, and among completers there was a trend for the highest dose to worsen [1]. It received an adopted name in 2002 but was not developed further for dementia; a later study on isolated human and pig detrusor tested it as a bladder antimuscarinic, where it antagonised carbachol-induced contraction of human detrusor with a pKb of 6.2 against 7.9 for oxybutynin [5].
Reputation
Held up as the most rational of the failed muscarinic agonists and, precisely because of that, the most damaging to the hypothesis. The design was correct in principle and it worked in rodents; it still produced cholinergic adverse events at every dose tested in patients. Its main modern use is as the counterexample cited whenever someone proposes that subtype selectivity at the acetylcholine site alone would have saved the class.
Subjective profileweighing the evidence above
A well-reasoned receptor-selectivity bet that delivered a clean animal profile, a workable dose, and zero cognitive benefit in 496 patients. It is worth knowing precisely because the design logic was sound and the result was still flat, which is the honest shape of the whole M1-agonist era.
Resources
This entry is here for reference.
Research
- 1997first citedActivating the posttraumatic cholinergic system for the treatment of cognitive impairment follo…
- 1998most active year4 papers
- 2000controlled trialLu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 St…
- 2002most recentActions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.
- 1.Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group.
- 2.A bridging study of LU 25-109 in patients with probable Alzheimer's disease.
- 3.In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro.
- 4.Lu 25-109, a combined m1 agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease.
- 5.Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.
- 6.Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
- 7.Metabolites of [14C]-5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine in mice, rats, dogs, and humans
- 8.Evaluation of blood-brain barrier passage of a muscarine M1 agonist and a series of analogous tetrahydropyridines measured by in vivo microdialysis
- 9.Activating the posttraumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury
- 10.Chronic administration of a partial muscarinic M1 receptor agonist attenuates decreases in forebrain choline acetyltransferase immunoreactivity following experimental brain trauma
10 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Does alvameline improve memory?
No. That was the whole point of the six-month trial in 496 people with probable Alzheimer's disease, and it showed no difference from placebo on either the cognitive scale or the global clinical impression. Nothing in the human record supports it as a memory drug.
Why did a drug with such a careful receptor design still fail?
Selectivity solved the side-effect problem it was aimed at without solving the disease. Propping up M1 signalling appears not to be enough once the cholinergic neurons themselves are dying, which is the same wall xanomeline, milameline and the rest of that generation ran into.
Can I buy alvameline?
Not as a medicine. It was never approved anywhere and development ended around 2000. It survives only as a laboratory reference compound sold to research suppliers.
Alvameline was designed to avoid cholinergic side effects. Why did it still cause them?
Because the doses involved were very high. Its binding affinity at M1 is in the nanomolar range but the concentration required to actually activate M1 in tissue is near two micromolar, a gap of roughly 200-fold, and the clinical trials used 25 to 150 mg three times daily. At those doses the M2 and M3 antagonism was not enough to keep peripheral cholinergic effects away, and salivation, dizziness and gastrointestinal symptoms were reported at every dose tested. Blocking one receptor while driving a weak partial agonist at another is a sound idea; it stops being one when the agonist arm needs orders of magnitude more drug than the binding data implies.
What did the phase 3 trial show?
Nothing helpful. A six-month randomised placebo-controlled trial randomised 496 patients with probable Alzheimer's disease at 29 centres to placebo or 25, 50 or 100 mg three times daily. Neither primary endpoint moved, the cognitive subscale of the Alzheimer's Disease Assessment Scale or the clinical global impression of change, and neither did the secondary measures. Among the patients who completed the study there was a trend for the highest dose to be worse than placebo, and adverse events increased with dose.
Can alvameline still be obtained?
No. It was never approved for any indication. Development for dementia ended after the phase 3 trial, and the later work on human bladder tissue did not lead to a urological product either.
How does alvameline relate to the newer M1 PAMs?
It is the strongest version of the argument they had to answer. Alvameline was not a blunt cholinergic; it was a deliberate attempt to get M1 activation while blocking M2 and M3, and in mice it worked, producing none of the tremor or salivation that non-selective agonists cause. It failed anyway, because reaching M1 activation at the acetylcholine site takes a dose that overwhelms the selectivity. TAK-071 and VU0486846 avoid the problem by never activating M1 directly at all; they bind a separate site and amplify the acetylcholine already released, weakly and only where release is happening.
Adverse effects
- No cognitive benefit at any dose in a 496-patient, six-month, placebo-controlled Alzheimer's trial
- A trend toward worse cognition at the highest dose among trial completers
- Dizziness, nausea, diarrhoea, fatigue, increased sweating and anorexia, all rising with dose
- Gastrointestinal effects capped dosing; 200 mg three times daily was stopped after three days
- Discontinued, never approved, and with no long-term human safety data of any kind
- Cholinergic adverse events at every dose tested in Alzheimer's patients, including increased salivation, dizziness and gastrointestinal symptoms
- Gastrointestinal effects stopped the 200 mg three times daily panel after three days
- Dizziness, nausea, diarrhoea, fatigue, sweating and anorexia all rose with dose in the phase 3 trial